I PREVENT - Irbesartan In Hypertensive Diabetic Patients
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
- To evaluate Blood Pressure (BP) reduction to the targeted values (Systolic BP ≤ 130 mmHg
and Diastolic BP ≤ 80 mmHg) in hypertensive type 2 diabetic patients.
- To evaluate the benefit of Irbesartan in the reduction of microalbuminuria from baseline
(if any at the inclusion visit) in this population.
- To demonstrate the safety of Irbesartan in this population.